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The induction of acute arthritis in rats by a single intraperitoneal injection of group A streptococcal cell wall
is associated with the activation of complement. We have therefore investigated the interaction of arthropathic
peptidoglycan-polysaccharide complex of streptococcal cell walls and human complement. The incubation of
cell wall in normal human serum results in the formation of complexes of cell wall and the C3 and C4
components of complement. Using agammaglobulinemic serum, we have further shown that the activation of
complement and formation of complement-cell wall complexes absolutely requires the presence of a small
quantity of specific antibody. This antibody is present in normal human immunoglobulin G and is effective as
the Fab fragment (alternative pathway). Although antibodies specific for three cell wall epitopes were capable
of inducing complement-cell wall complex formation by the classical complement pathway, only anti-A
polysaccharide antibody (N-acetyl-D-glucosamine epitope) was effective by the alternative complement path-
way. A complement consumption assay showed that anti-cell wall antibody was required not only for
complement-cell wall complex formation, but also for activation of complement by streptococcal cell wall in
human serum. These studies suggest that a minimal level of anti-cell wall antibody may be required for the
induction of arthritis in rats by streptococcal cell wall.
Complement activation plays an important role in the
pathogenesis of inflammatory arthritis induced by a single
systemic injection of an aqueous suspension of group A
streptococcal cell walls in rats. During day 1 after cell wall
injection, there is an initial decline in serum complement, as
measured by both the classical and alternative pathways
(17). After 2 days, the serum complement recovers and in
fact rises to levels more than twice as high as normal. The
depletion of complement over the short term by multiple
injections of cobra venom factor depresses the acute phase
of the group A cell wall-induced arthritis (26). However, the
complement suppression is short-lived, and the chronic
inflammatory arthritis that develops in cobra venom-treated
animals is indistinguishable from that in controls given only
cell wall. In addition, cell wall-complement complexes are
present in the tissues of arthritic rats (Eisenberg and
Schwab, manuscript in preparation). Such complement-cell
wall complexes have also been suggested by in vitro work
showing that cell wall incubated in serum is able to bind to
cellular complement receptors (22).
Because of the involvement of complement in group A cell
wall-induced acute arthritis in rats, we have been interested
in investigating the mechanisms of complement activation by
the arthropathic cell wall. A variety of bacteria or bacterial
cell walls, as well as the isolated peptidoglycan, have been
shown to be activators of the alternative complement path-
way (9, 11). In some cases, an enhancing role for antibody
has been demonstrated in this activation (29). In other cases,
antibody is absolutely required (6). Some nonbacterial acti-
vators of the alternative pathway have also been shown to
have either enhanced activation in the presence of specific
antibody (20) or an absolute requirement for antibody (19).
In the current investigation, we have focused on the activa-
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tion of human complement by streptococcal cell wall, since
appropriate human reagents are readily available. We have
found that the arthropathic peptidoglycan-polysaccharide
complex of group A streptococcal cell wall absolutely re-
quires antibody for activation of either the classical or the
alternative complement pathway and the subsequent forma-
tion of cell wall-complement complexes. Although the spec-
ificity of the anti-cell wall antibody is critical, sufficient
activating antibody is present in normal human serum or
normal human immunoglobulin G (IgG).
MATERIALS AND METHODS
Cell wall. Group A type 3 strain D58 streptococci were
processed as previously described (10) to obtain arthropathic
cell wall fragments, which consisted essentially of peptido-
glycan covalently bound to the group A polysaccharide (14).
In some experiments, cell wall was prepared in similar
fashion from group A variant streptococci, which lack most
of the N-acetyl-D-glucosamine (NADG) determinant, which
is the characteristic epitope of the group A polysaccharide
(3). Peptidoglycan was also prepared from group A variant
cell wall by extraction of the group A variant polysaccharide
with hot formamide (15).
Sera. Serum from three normal donors was used. In
addition, samples were obtained from a 42-year-old female
patient with severe agammaglobulinemia secondary to com-
mon variable immunodeficiency. The serum immunoglobulin
levels of this patient were as follows: IgG, 20 ,ug/ml; IgA, 70
pugIml; IgM, 30 ,ug/ml; and IgE, less than 1 U/ml. Serum and
heparinized plasma were used interchangeably with entirely
comparable results. In experiments in which the agam-
maglobulinemic serum was utilized, serum from the patient's
husband, which had been obtained at the same time and
processed in parallel, was used as a control.
Antibodies. Polyclonal human IgG was a DEAE-purified
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FIG. 1. Formation of complement-cell wall complexes in normal humnan serum. Group A streptococcal cell wall (100 ,ug) was mixed with
human serum and incubated for the indicated periods of time. C4- and C3-cell wall complexes were measured by ELISA as described in the
text. 0, Normal human serum; 0, normal human serum plus 0.01 M EDTA; A, normal human serum plus 0.01 M EGTA and 0.005 M Mg2";
A, normal human serum heated to 50°C for 20 min; *, normal human serum heated to 50°C for 20 min plus 0.01 M EGTA and 0.005 M Mg2+.
O.D.405, Optical density at 405 nm.
preparation made from commercial Cohn FIl. In one exper-
iment, the Fab fragments prepared by papain digestion of the
DEAE-purified IgG from a single individual were utilized.
Specific antibodies to the group A polysaccharide (NADG),
the group A variant polysaccharide (rhamnose oligosaccha-
ride), and peptidoglycan (D-Ala-D-Ala) were affinity purified
from rabbit sera as previously described (8). Human com-
plement components were detected by monoclonal antibody
to C4 (the kind gift of J. Donald Capra, Dallas, Tex.) or with
a polyclonal affinity-purified rabbit anti-human C3.
Formation of cell wall-complement complexes. Group A cell
wall fragments were added to human serum samples at a
concentration of 100 ,ug/ml on ice. The serum was then
placed at 37°C for 1 h, except in those studies in which
multiple times of incubation were tested. At the end of the
incubation time, sufficient 0.1 M EDTA was added to yield a
final concentration of 0.01 M EDTA, and the tubes were held
on ice until they were ready for testing. Sera were also
incubated with cell wall after the following manipulations:
the addition of 0.01 M ethylene glycol-bis(aminoethyl ether)-
N,N,N',N')tetraacetic acid (EGTA)-0.005 M Mg2+ to test
only the alternative pathway; the addition of 0.01 M EDTA
as a negative control; heating to 50°C for 20 min to test only
the classical complement pathway; heating to 50°C for 20
min and the addition of 0.01 M EGTA-0.005 M Mg2' as a
negative control; and heating at 56°C for 30 min as a negative
control. At least one form of negative control was included
in every experiment.
ELISA. The streptococcal cell wall-complement com-
plexes were detected by an enzyme-linked immunosorbent
assay (ELISA) adapted from the radioimmune assay for cell
wall previously described (8). Polyvinyl flat-bottom microti-
ter plates (96 well; Dynatech Corp., Alexandria, Va.) were
coated with a 3-,ug/ml solution of anti-C4 or anti-C3 or with
anti-group A cell wall in borate-buffered saline (1 ,ugIml; 0.2
M borate, 0.075 M NaCl [pH 8.4]) for 5 h at 4°C. Nonspecific
binding sites were then blocked by the addition of 200 ,ul of
borate-buffered saline plus 0.5% human serum albumin,
0.4% Tween 80, and 0.01 M EDTA (BHTE) per well. Then
samples were added in 100 ,ul at a dilution of 1:1,000 in
BHTE. After overnight incubation, affinity-purified biotinyl-
ated antibodies to group A cell wall were added for 3 h at
4°C. Avidin-alkaline phosphatase conjugate (100 ,ul) was
then added for a further incubation of 3 h at 4°C. Finally, 100
,ul of para-nitrophenyl phosphate at 1 mg/ml in 0.01 M
diethanolamine (pH 9.8) was added. The development of
color was monitored by an automated microELISA reader
(Dynatech model MR 580). All results shown are the net
optical density, calculated by subtracting the appropriate
assay background in each case. Control assays confirmed
the requirement for cell wall, complement, and specific
antibodies in these assays.
Erythrocyte lysis assay. Consumption of hemolytic com-
plement via the alternative pathway was determined by
rabbit erythrocyte lysis (5). Agammaglobulinemic serum
plus EGTA-Mg2+ was incubated alone, with 100 ,ug of group
A streptococcal cell wall per ml, with 40 ,ug of rabbit anti-A
polysaccharide affinity-purified antibody per ml, or with both
cell wall and antibody for 180 min at 37°C. After incubation,
the samples were tested for residual hemolytic complement
by making serial 1.5-fold dilutions in EGTA-Mg2+ and then
adding an equal volume of 1% washed normal rabbit eryth-
rocytes in Veronal-buffered saline-EGTA-Mg2+. After incu-
bation at 37°C for 30 min, the plates were centrifuged at
2,500 rpm (J6B centrifuge; Beckman Instruments, Inc., Palo
Alto, Calif.) for 5 min, and 15 ,ul of the supernatants was
transferred to clean, flat-bottom microtiter wells for deter-
mination of released hemoglobin by the microELISA reader.
RESULTS
Formation of complement-cell wall complexes in normal
human serum. The incubation of group A streptococcal cell
wall in human serum resulted in the formation of C4-cell wall
complexes by the classical complement pathway and C3-cell
wall complexes by both the classical and alternative com-
plement pathways. The C4 complexes were formed within
minutes in serum with an intact classical pathway and did
not decrease appreciably thereafter (Fig. 1). The C3 com-
plexes were also rapidly formed, but decreased over a period
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FIG. 2. IgG requirement for formation of complement-cell wall complexes in agammaglobulinemic human plasma. Cell wall was incubated
in agammaglobulinemic plasma treated to permit only classical complement pathway activation (50°C for 20 min [0, 0]) or only alternative
complement pathway activation (EGTA-Mg2+ [A, A]). 0 and A, Addition of 8 mg of normal human IgG per ml; * and A, addition of buffer.
C4- and C3-cell wall complexes were measured by ELISA at the indicated times. O.D.405, Optical density at 405 nm.
Requirement for immunoglobulin for cell wall-complement
complex formation. The availability of serum and plasma
from a patient with unusually low levels of serum immuno-
globulin permitted us to investigate the role of antibody in
the formation of cell wall-complement complexes. Initial
observations showed that the agammaglobulinemic serum
failed completely to form cell wall-complement complexes
with C3 and C4 by either the classical or alternative com-
plement pathway. However, by adding normal human IgG to
a concentration of 8 mg/ml, the complement-activating ca-
pacity of the agammaglobulinemic serum was restored (Fig.
2). The agammaglobulinemic serum plus IgG formed C4-cell
wall complexes in the presence of the classical complement
pathway and formed C3-complement complexes in the pres-
ence of either the classical or the alternative complement
pathway. In the absence of additional immunoglobulin, no
complement-cell wall complexes were formed for the entire
6 h of the experiment. In addition, C4-complenment com-
plexes were never formed in the presence of the alternative
complement pathway. Fab fragments of serum IgG also
permitted the formation of C3-cell wall complexes (but not
C4 complexes) in unmanipulated plasma or in EGTA-Mg2+
plasma (data not shown).
Specific antibody required for complement activation. The
addition of normal IgG to agammaglobulinemic serum to
restore the ability of the serum to form cell wall-complement
complexes via alternative pathway activation suggested that
anti-cell wall antibody might be required. This interpretation
was further supported by the fact that preabsorption of
normal human IgG with cell wall specifically removed its
complement-activating ability by both the classical and
alternative pathways (data not shown). The specificity of this
antibody requirement was investigated by adding graded
concentrations of three preparations of affinity-purified rab-
bit anti-cell wall antibody to agammaglobulinemic plasma
and testing for the formation of C4- and C3-cell wall com-
plexes by either the alternative or classical complement
pathway. Antibodies against the A polysaccharide (NADG),
the A variant polysaccharide (rhamnose oligosaccharide), or
the D-Ala-D-Ala determinant of the peptidoglycan all were
capable of the induction of complement activation via the
classical pathway and the subsequent formation of C4- and
C3-cell wall complexes (Fig. 3). On the other hand, only the
anti-A polysaccharide antibody was efficient at inducing
activation via the alternative complement pathway. The
anti-A variant antibody induced some activation via the
alternative complement pathway at the highest concentra-
tion, whereas the anti-D-Ala-D-Ala antibody was completely
ineffective. The loss of complex detection at the highest
concentration of the anti-A antibody was presumably due to
competition of the added antibody with the biotinylated
anti-A antibody used to develop the ELISA, since an anti-
cell wall assay on this material was similarly inhibited (data
not shown).














IC I I I
0.4 4 40 400 0.4 4 40 400
IqG ADDED (,ug/ml)
0.4 4 40 400
FIG. 3. The role of specific antibody in the formation of comple-
ment-cell wall complexes in agammaglobulinemic plasma. The indi-
cated quantities of affinity-purified rabbit antibody specific for group
A polysaccharide (anti-APS)i A variant polysaccharide (anti-
AVPS), or D-Ala-D-Ala terminus of the pentapeptide of peptidogly-
can (anti-D-Ala-D-Ala) were incubated with agammaglobulinemic
plasnma and 100 ,ug of group A streptococcal cell wall per ml for 1 h
at 37°C. C3- and C4-cell wall complexes were measured by ELISA.
0, Plasma heated to 50°C for 20 min; *, plasma plus EGTA-Mg2+.
O.D.405, Optical density at 405 nm.
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FIG. 4. Specificity of antibody required for the formation of
complement-cell wall complexes with different cell wall prepara-
tions. (A) Group A streptococcal cell wall; (B) group A variant
streptococcal cell wall; (C) group A variant peptidoglycan. Cell wall
was incubated with indicated specific antibodies at 40 ,ug/ml and
agammaglobulinemic serum for 1 h at 37°C and then tested for C4-
and C3-cell wall complexes. Classical pathway activation was
determined in serum that had been heated to 50°C for 20 min,
whereas alternative pathway activation was determined in serum to
which had been added EGTA-Mg2+. E2, Normal human serum; O,
agammaglobulinemic serum plus normal rabbit IgG; 1, agam-
maglobulinemic serum plus anti-A polysaccharide antibody; *,
agammaglobulinemic serum plus anti-A variant polysaccharide an-
tibody; E, agammaglobulinemic serum plus anti-D-Ala-D-Ala anti-
body. OD405, Optical density at 405 nm.
preparations were combined with the affinity-purified rabbit
anti-cell wall antibodies in the presence of agamma-
globulinemic serum. The antibodies were all used at a
concentration of 40 ,ug/ml. Figure 4A shows the results with
group A streptococcal cell wall. As previously indicated
(Fig. 3), activation via the classical complement pathway
could be obtained with antibodies to the A polysaccharide, A
variant polysaccharide, or peptidoglycan. However, only
antibodies to A polysaccharide were able to induce the
formation of C3-cell wall complexes by the alternative
pathway. This restriction was true even though the anti-
peptidoglycan antibodies were as good inducers of the
classical pathway as the anti-A polysaccharide antibodies.
With group A-variant cell wall, the results were somewhat
different (Fig. 4B). This material is not well recognized by
the anti-A polysaccharide antibody, and therefore this anti-
body was unable to activate complement by either pathway.
Group A variant cell wall is recognized by both the anti-A
variant polysaccharide antibodies and the anti-peptidoglycan
antibodies, and both of these preparations produced efficient
C4- and C3-cell wall complex formation by the classical
complement pathway. However, only the anti-A variant
polysaccharide antibody was able to induce the formation of
C3-cell wall complexes by the alternative complement path-
way. The results for A variant peptidoglycan (Fig. 4C) are
qualitatively similar to those for the A variant cell wall,
presumably because, as we have previously found, the A
variant peptidoglycan preparation is contaminated with A
variant polysaccharide and therefore is recognized by both
the anti-A variant polysaccharide antibody and the anti-
peptidoglycan antibody (unpublished results).
Consumption of hemolytic complement by the alternative
and classical complement pathways. Up to this point, we have
been using the concepts of complement activation and
formation of C4- and C3-cell wall complexes interchange-
ably. This usage was based on the assumption that if the
streptococcal cell wall was able to activate complement in
serum, it would lead to the formation of such complexes. In
a further set of experiments, we tested this assumption by
measuring complement activation (i.e., consumption) di-
rectly in agammaglobulinemic serum via the alternative
complement pathway. Agammaglobulinemic serum was in-
cubated in the presence of EGTA-Mg2+ for 3 h at 37°C.
Serum samples were premixed with group A streptococcal
cell wall alone, cell wall plus anti-A antibody, anti-A anti-
body alone, or neither cell wall nor antibody. These samples
were compared with agammaglobulinemic serum which was
held on ice during the 3 h. Serial dilutions of each sample
were tested for the ability to lyse rabbit erythrocytes in the
presence of EGTA-Mg2+, as a measure of hemolytic com-
plement initiating through the alternative complement path-
way. There was a slight loss in hemolytic complement in the
serum samples that had been incubated at 37°C, but it made
no difference whether there had been antibody present, cell
wall present, or neither (Fig. 5). Only that serum sample
which had both antibody and cell wall showed marked
complement consumption. This experiment supports our
assumption that the failure to form cell wall-complement
complexes was indicative of a failure to activate comple-
ment.
DISCUSSION
We have found that group A streptococcal cell walls,
which are capable of inducing a chronic inflammatory de-
structive arthritis when injected into rats (4), can activate
complement in human serum by both the classical and
alternative pathways and can form complexes containing cell
wall and the C4 and C3 complement components. In serum,
the C4 component of the complex is relatively stable over 3
days at 37°C, whereas the C3 determinants are gradually
lost. This catabolism of C3 probably represents, at least in
VOL. 53, 1986




































30 chain) showed little or no alternative complement pathway
activation with group A streptococcal cell walls, although
both of these antibodies were good activators of the classical
complement pathway. On the other hand, the anti-A variant
antibody provided excellent alternative complement path-
way activation with A variant cell walls. Therefore, the
relative activities of these antibodies vis-a-vis the alternative
complement pathway are a function of both their binding
specificity (21) and the molecular structure of the substrate
with which they interact.
Studies with several normal sera, as well as with prepara-
- -~~- - - - - tions of human IgG from individuals not specifically immu-
/--~~~-> o nized against streptococcal cell wall antigens, indicate that
/ f,/o / '"the antibodies required for alternative complement pathway
so_/ / activation were present as part of background serum immu-DO / /noglobulins. The actual level of specific antibody necessary
/ Dl / for alternative pathway activation was approximately 40
,g/ml, although much lower amounts of anti-peptidoglycan
antibody were effective for classical pathway activation. The
absorption experiments with normal human IgG indicated
that the active principle was indeed specific antibody. Fi-
nally, the finding that Fab fragments of antibody were also
effective in alternative complement pathway (but not classi-
cal complement pathway) complex formation was in agree-
ment with previous systems in which antibody has been
shown to play a facilitating role for the alternative comple-
ment pathway (23).
Most activators of the alternative pathway are believed to
proceed by an antibody-independent route. However, sev-
o0 10 20 40 eral bacterial substrates have been found to require antibody
% PLASMA ADDED for alternative complement pathway activation (1, 2, 6, 7, 13,23, 24, 27, 28). The killing of Escherichia coli in bovine
i. Consumption of complement by the alternative pathway serum via the alternative complement pathway was shown to
ococcal cell wall requires antibody. Agammaglobulinemic require a factor specifically absorbable at 0°C with homolo-
iith EGTA-Mg2l was incubated for 3 h at 37°C, and then
Iytic complement activity via the alternative pathway was gous bacterla (13), whereas in similar experiments with
I by testing serial 1.5-fold dilutions for lysis of rabbit Shigella spp. in human serum, it was possible to restore the
ytes (RBC) in the presence of EGTA-Mg2+. 0, Plasma plus opsonic capacity of absorbed serum with IgM antibody (24).
anti-A polysaccharide antibody per ml and 100 ,ug of cell In studies with Haemophilus influenzae, it was shown that
ml; *, plasma plus cell wall alone; O, plasma plus anti-A the alternative complement pathway was activated by en-
alone; *, plasma plus neither cell wall nor antibody; A, capsulated strains in C4-deficient guinea pig serum, but
eld at 4C before being tested.OD405,Optical density at 405 killing of the bacteria occurred only in the presence of
anti-polysaccharide antibody (28). More recent work with H.
influenzae type B in human serum showed that activation
action of factors H and I, as C3c is lost preferen- and killing by the alternative complement pathway were
C3dg, particularly in the presence of erythrocytes absolutely antibody dependent (27). In addition, this last
,t shown; 16, 18, 25). We are confident that our study found that the alternative complement pathway re-
were able to separate reliably the classical and quired anti-capsular antibodies specifically, while classical
ive complement pathways since (i) EGTA-treated pathway-mediated killing could proceed with either anti-
iever permitted C4 complex formation; (ii) serum capsular antibodies or other antibodies that reacted with the
it 50°C for 20 min permitted C4 complex formation, bacterial organism. These results are entirely parallel to our
not permit C3 complex formation in the presence of findings with group A streptococcal cell wall. Another study
,ments; and (iii) the combination of EGTA-Mg2+ and measured the role of the alternative complement pathway in
20-min treatments resulted in inactivation of both the opsonophagocytosis of type III group B streptococcus
/s. (6, 7). This investigation found that in organisms with intact
ave also shown that specific anti-cell wall antibody sialic acid residues in the capsular polysaccharide, anti-type-
iolutely required for activation of the alternative specific antibody was required for alternative complement
nent pathway by the streptococcal cell wall. No pathway activation. However, if these sialic acid residues
ive pathway activation or formation of C3-cell wall were removed, the bacteria could be opsonized by the
ces occurred in agammaglobulinemic serum. Using alternative complement pathway in the absence of antibody.
purified rabbit antibodies specific for three im- Both this study and the study of H. influenzae (27) showed
terminants of the group A streptococcal cell wall, we that the quantity of antibody necessary for alternative com-
hat only anti-NADG antibodies could activate the plement pathway activation was greater than that needed for
ive pathway efficiently. Anti-A variant antibodies the classical complement pathway. This result again is in
recognize the polyrhamnose backbone of the poly- agreement with our results with the streptococcal cell wall
ide) and anti-peptidoglycan antibodies (which recog- (Fig. 4).
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serum similarly forms complexes with the C3 complement
component by both the alternative and classical pathways.
In addition, such complexes are present in the tissues,
particularly the joints, of arthritic rats (Eisenberg and
Schwab, in preparation). Although we do not have the
appropriate reagents to prove directly a requirement for
antibody in alternative complement pathway activation in rat
serum, we feel this requirement is a reasonable assumption.
This situation then sheds a new light on the potential role of
antibody in the production of chronic inflammatory arthritis
in cell wall-injected rats. Our previous studies have shown
no obvious positive correlation between overall antibody
titers and the development of disease (12). On the other
hand, IgM anti-peptidoglycan antibody levels in the chronic
phase ofjoint disease appear to have a suppressive effect on
the further development of chronic arthritis (R. E. Esser,
S. K. Anderle, R. A. Eisenberg, and J. H. Schwab, Abstr.
Annu. Meet. Am. Soc. Microbiol. 1984, B22, p. 21). Our
present results suggest that a minimal antibody level is
required for activation of complement by either the classical
or the alternative pathway. Therefore, as complement plays
a role in the production of disease (26), it is likely that natural
antibody is also essential. Since the levels of antibody
necessary are quite small (e.g., less than 1 ,ug of anti-
peptidoglycan per ml for the classical pathway activation)
and since such antibodies are presumably formed in the
course of exposure to environmental agents, it would prob-
ably be difficult to demonstrate directly such a requirement
in vivo.
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